Psychedelics

Article: Psilocybin reproducibility | Cannabis Law Report


The renewed interest in psilocybin for the treatment of psychiatric conditions has highlighted a lack of robustness and reproducibility in reports of its behavioural effects. In this study, Lu et al. coordinated five independent laboratories to assess the previously reported acute and persistent behavioural effects of psilocybin in mice using standardized behavioural assays that are commonly used to assess depression and anxiety-like phenotypes in animal models.

In line with previous reports, the acute effects of psilocybin (detected in the first 15 min after administration) — increasing anxiety-related avoidance and decreasing fear expression — were observed consistently across laboratories. However, psilocybin’s reported persistent effects — including the alleviation of anxiety-like and depression-related behaviours, facilitation of fear extinction, enhanced social preference and reopening of a critical period for social reward learning in adult mice — were inconsistently observed.

Read full article: https://www.nature.com/articles/s41583-026-01109-2



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

strain roundup

Breaking News

  Federal Drug Policy, April 2026: The Operative Architecture of Cannabis Rescheduling, the Psychedelic Therapeutic Acceleration Directive, and the Road to June 29 RN...

cannabis business

As the end of November approaches you can feel the buzz amongst cannabis industry circles about the yearly pilgrimage we all make to Las...

Pot Luck

Digital entertainment offers an extraordinary range of conversations, formats and destinations. For a reader interested in Chinese-language online culture, that variety can be appealing...

Exit mobile version